Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Doctolib SAS
Doctolib is a French health-tech company that lets patients book doctor appointments online and gives doctors software to run their practices.
Doctolib is the booking layer for healthcare in France. If you live there and need to see a doctor, a dentist, or a physiotherapist, there is a good chance you open Doctolib, type in what kind of care you need and where you are, and pick a time slot. For patients, the service is free. For the doctors and clinics on the other side, it is a paid tool that does far more than fill a calendar — it handles scheduling, patient records, reminders, and the administrative plumbing that keeps a practice running.
The business model is simple at its core. Doctors and clinics pay a monthly subscription to use the software, and in exchange they get fewer no-shows, less time wasted on the phone, and a stream of new patients who found them through the platform. That creates a two-sided flywheel: more patients make the platform more valuable to doctors, and more doctors make it more useful to patients. Doctolib is not a marketplace that takes a cut of each visit — it charges for the software itself, which keeps the incentives clean and the revenue predictable. The company has expanded well beyond France. It operates in Germany and Italy too, and it has pushed into adjacent services like teleconsultation and practice-management tools, betting that the doctor's desktop is a durable place to sit. That expansion has not been smooth everywhere: in Germany, doctors' associations have pushed back on how appointment data is used, and regulators across Europe keep a close eye on anything touching health records. Those are real risks for a company whose whole value proposition rests on trust.
Doctolib was founded in 2013 by Stanislas Niox-Chateau and two partners, and it has grown into one of France's most valuable private tech companies, backed by investors including General Atlantic and Eurazeo. It is not publicly traded, so there is no ticker and no share price to watch — the measure of its success is how many appointments flow through its pipes and how deeply doctors depend on its software. The simple version: it turned the messy business of booking a doctor's visit into something that feels as easy as ordering a ride, and it gets paid by the people on the supply side who benefit most from that ease.
Saved answer · last researched 10 Nov 2026